Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Extended-release calcifediol identifies a therapeutic vitamin D range in chronic kidney disease stages 3 and 4.
Journal: Clinical kidney journal
Published: February 12, 2026
Managing Dysregulated Vitamin D Metabolism in CKD: Time to Update Conventional Wisdom?
Journal: Kidney360
Published: August 26, 2025
Effect of race, gender and age on intrinsic diurnal variation of serum calcifediol: Insights into vitamin D toxicity.
Journal: The Journal of steroid biochemistry and molecular biology
Published: August 18, 2025
High-dose extended-release calcifediol successfully treated advanced secondary hyperparathyroidism in an end-stage kidney disease patient: a case report.
Journal: BMC nephrology
Published: March 29, 2025
Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial.
Journal: American journal of nephrology
Published: March 20, 2025
Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial.
Journal: American journal of nephrology
Published: December 11, 2024
Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients.
Journal: American journal of nephrology
Published: July 26, 2024
Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism.
Journal: Nephron
Published: November 24, 2023
Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease.
Journal: Kidney diseases (Basel, Switzerland)
Published: September 15, 2022
Factors in nephrologists' decision to treat pre-dialysis CKD patients with vitamin D insufficiency and SHPT: A discrete choice experiment.
Journal: PloS one
Published: July 27, 2022
REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients.
Journal: Nutrition (Burbank, Los Angeles County, Calif.)
Published: July 11, 2022
Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients.
Journal: BMC nephrology
Published: March 21, 2022
Last Updated: 09/26/2026